Beryl Drugs opened higher at ₹26.00, compared with its previous close of ₹25.34. In the last trading session on 12 Nov 2026, the stock traded between ₹24.00 and ₹26.00, with an average traded price of ₹24.02. It showed a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Beryl Drugs is now worth
₹ 18,605.00
Giving a profit of
₹ 8,605.00 (86.05%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-1.34 (-5.29%)
Day High
₹26.00
Day Low
₹24.00
Day Open
₹26.00
Prev Close
₹25.34
Volume
12,247
Value Traded
₹0.03 Cr
1W Return
3.27%
1M Return
-8.78%
3M Return
0.00%
6M Return
19.64%
1Y Return
2.30%
Market Cap (₹ Cr.)
12
PE Ratio
20.60
PB Ratio
1.30
Dividend Yield
-
ROE
4.30%
ROCE
8.89%
Book Value (₹)
19.45
Face Value (₹)
10.00
EPS (TTM)
-
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
3.27%
6 Weeks
-
1 Month
-8.78%
3 Months
0.00%
9 Months
9.69%
No data available.
Beryl Drugs shareholders raise related party transaction limit to ₹8 crore
Material related party transaction limit with Aminova Infusions raised to ₹8 crore. Audited financial statements for FY26 adopted by shareholders. Sudhir Sethi reappointed as director retiring by rotation. Voting conducted via remote e-voting and poll with 47 members attending.
1mo agoBeryl Drugs schedules 33rd AGM for September 29, 2026 in Indore
Beryl Drugs Limited will hold its 33rd AGM on September 29, 2026, in Indore. Share transfer books remain closed from September 23 to September 29, 2026. Remote e-voting is open from September 26 to September 28, 2026. Shareholders must hold shares as of the September 22, 2026 cut-off date.
2mo agoBeryl Drugs net profit falls 25% in FY26 to ₹42.48 lakh
Net profit fell 25% YoY to ₹42.48 lakh in FY26 due to BFS shutdown. Total revenue declined 14% to ₹1,931.02 lakh; EPS dropped to ₹0.84. Long-term borrowings fully repaid; short-term debt stands at ₹239.13 lakh. Shareholders to vote on raising RPT limit with Aminova Infusions to ₹8 crore.
2mo agoBeryl Drugs promoter Sudhir Sethi acquires 4809 shares in open market
Beryl Drugs Limited reported that promoter Sudhir Sethi purchased 4809 shares on August 18, 2026. Executed via market transactions, the deal raised his stake from 10.14% to 10.24%. The filing complies with SEBI's substantial acquisition regulations.
2mo agoBeryl Drugs net profit jumps 946% in Q1FY27 on revenue growth
Beryl Drugs Limited posted a 946% year-on-year increase in net profit to ₹22.08 lakh for Q1FY27, aided by a 56% rise in revenue to ₹75.66 lakh. Profit before tax also expanded significantly to ₹26.98 lakh from ₹6.97 lakh in the prior year period. The results were approved by the Board on August 11, 2026, following a limited review by statutory auditors.
3mo agoBeryl Drugs website temporarily unavailable due to technical issue
Beryl Drugs Limited reported on July 20, 2026, that its website is temporarily unavailable due to an unexpected technical issue. The company confirmed that business operations and financial systems remain unaffected and that restoration activities are underway. The disclosure was made pursuant to Regulation 30 of the SEBI LODR Regulations, 2015.
3mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,899.30 | +0.76% | ₹4,55,705.69 | 41.20 | +9.65% | |
| ₹11,495.00 | +0.09% | ₹3,05,156.13 | 90.40 | +76.30% | |
| ₹4,685.20 | -0.89% | ₹1,78,209.95 | 85.50 | +22.50% | |
| ₹2,427.00 | +1.13% | ₹1,31,133.78 | 97.10 | +145.34% | |
| ₹1,204.50 | -0.12% | ₹1,20,149.34 | 28.00 | +26.60% | |
| ₹1,388.30 | +0.12% | ₹1,15,878.66 | 42.00 | +12.91% | |
| ₹1,409.80 | +0.11% | ₹1,13,891.88 | 39.90 | -7.21% | |
| ₹2,663.30 | +0.94% | ₹1,10,006.30 | 48.10 | +17.33% | |
| ₹1,808.90 | +0.09% | ₹1,04,080.11 | 26.00 | +52.83% | |
| ₹2,019.10 | +0.20% | ₹92,331.42 | 17.60 | -0.73% | |
| ₹2,639.00 | -0.78% | ₹74,479.09 | 51.60 | +42.82% | |
| ₹5,194.00 | -2.04% | ₹62,102.06 | 30.50 | -9.94% |
An investment of ₹10,000 made 5 years ago in Beryl Drugs is now worth
₹ 18,605.00
Giving a profit of
₹ 8,605.00 (86.05%)
Note: Past profits do not guarantee future returns.
